Introduction: Established evidence suggests that gut microbiota plays a role in ulcerative colitis (UC). Fecal microbiota transplantation (FMT) is clearly recognized as a highly effective treatment for patients with recurrent Clostridium difficile infection and has been investigated also in patients with UC, with promising results.Areas covered: Literature review was performed to select publications concerning current evidence on the role of gut microbiota in the pathogenesis of UC, and on the effectiveness of FMT in this disorder.Expert opinion: The randomized controlled trials published investigating the use of FMT suggested a potential role for FMT in the treatment of mild to moderate UC. However, given several unanswered questions regarding donor selection, dose, route of administration and duration of therapy, this is not yet recommended as a viable therapy option. FMT has allowed for more in depth investigation with regards to the role the gut microbiota may be playing in UC. This knowledge is critical to identifying where FMT may appropriately fit in the UC treatment paradigm. As our understanding of the role the microbiome plays in this chronic disease, FMT, and then eventually defined microbes, will hopefully serve in a complementary role to conventional IBD therapies.

中文翻译：

---

溃疡性结肠炎的粪便移植：当前证据和未来应用。

简介：已有证据表明肠道菌群在溃疡性结肠炎（UC）中起作用。粪便菌群移植（FMT）显然被认为是复发性艰难梭菌感染患者的一种高效治疗方法，并且在UC患者中也进行了研究，结果令人鼓舞。肠道菌群在UC发病机理中的作用以及FMT在该疾病中的有效性。专家意见：发表的调查使用FMT的随机对照试验表明FMT在轻度至中度UC的治疗中具有潜在作用。但是，鉴于有关捐赠者选择，剂量，给药途径和治疗持续时间的几个悬而未决的问题，尚不建议将其作为可行的治疗选择。FMT允许对肠道菌群可能在UC中扮演的角色进行更深入的研究。该知识对于确定FMT在UC治疗范例中适当适合的位置至关重要。当我们了解微生物组在这种慢性疾病中的作用时，FMT，然后是最终确定的微生物，有望与传统的IBD治疗相辅相成。